

Learn more

④ Pharmaceutical Industry Regulatory Information

④ Trends in obesity treatment development

④ GLP-1 Therapeutics Market Analysis

④ Corporate Investment Analysis

④ Biotechnology Licensing

④ Technology transfer contract consulting

④ Bio-company investment consulting

④ Pfizer and Novo Nordisk investments

④ Novo Nordisk Stock Analysis

④ obesity treatment



cancer

Celltrion's solid tumor ADC drug candidate 'CT-P73' has received approval for phase 1 clinical trials in Korea.

Reporter Ji Yong-jun | Posted 2025.11.10 15:42 | Last updated on November 10, 2025, at 3:45 PM | Comments 0



Phase 1 clinical trial of CT-P73 monotherapy in adult patients with advanced solid tumors



A panoramic view of Celltrion's second factory (Source: Celltrion)


Most viewed news

- 1 Dong-A ST's Type 2 Diabetes Treat...
- 2 Pfizer Wins Final Battle for Messer...
- 3 Olix received Phase 1 CSR for its ...
- 4 Celltrion completes final review of ...
- 5 Celltrion Holdings has decided to ...
- 6 "Wigobi," a dietary supplement, sim...
- 7 MSD's oral PCSK9 inhibitor, Enliciti...
- 8 ImmuneOncia applies for orphan d...
- 9 Iboneximab Improves OS by 26% i...
- 10 Following Boehringer and Roche, n...

Delegate Low-Level Tasks in BD,
Market Research and Investment to AI
— and Survive the Future



SINGULARITY
BIOTECH



AstraZeneca

Bristol Myers Squibb®

Pfizer
한국화이자제약

CSK

EON 7 Builder Floors in Emaar Emerald Hills Sec 62 Gurugram

EON Developers | Sponsored

[Read the next document >](#)

According to industry sources on the 10th, Celltrion received approval from the Ministry of Food and Drug Safety for its domestic Phase 1 clinical trial (Investigational New Drug) for CT-P73. This clinical trial will evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and initial efficacy of CT-P73 monotherapy in adult patients with advanced solid tumors. Celltrion anticipates that the drug will be effective in cancers such as cervical, head and neck, and colorectal cancers.

CT-P73 is an ADC therapeutic candidate that targets a specific tissue factor highly expressed in cancer cells and induces a payload (cytotoxic anticancer drug) linked to an antibody via a linker to attack cancer cells. The company is developing CT-P73 as a "best-in-class" drug.

Through open innovation, Celltrion applied PBX-7016, a novel camptothecin-derived topoisomerase (TOP1) inhibitor payload jointly developed with domestic biotech company PinoBio, to CT-P73. TOP1 inhibitors are drugs that kill cancer cells by damaging DNA and inhibiting their spread.

Celltrion unveiled preclinical results for CT-P73 at World ADC in June. The company explained that CT-P73 achieved significant results in terms of the therapeutic index (TI), a comprehensive assessment of efficacy and safety, based on low toxicity and superior efficacy.

Furthermore, based on the proven stability of the linker, superior pharmacodynamic properties were confirmed. Furthermore, Celltrion expects that CT-P73 administration will demonstrate excellent tumor penetration as well as a bystander effect, destroying surrounding cancer cells.



Reporter Ji Yong-jun (jyj@thebionews.net)

See other articles by this reporter

Copyright © The Bio. Unauthorized reproduction and redistribution prohibited.

Learn more

[Obesity treatment-related materials](#) [Obesity Management Program](#)

[obesity treatment](#) [Pfizer and Novo Nordisk investments](#)

[Pharmaceutical development consulting](#)

[Legal services related to mergers and acquisitions](#) [Diabetes treatment](#)

[Bio-company investment consulting](#)

[Pharmaceutical company recruitment information](#) [Bio-industry specialized training](#)

0 comments

Member Login

Author

password

Posting content that violates rights, contains profanity, or disparages specific individuals may result in sanctions under the Terms of Service and applicable laws. Logging in makes it easier to leave comments.



BORYUNG



Latest News

- Huons Group is holding a CSAT cheeri...
- K-MediHub Develops 'KD01', a Fluores...
- Pharma Research's third-quarter opera...
- Korea United Pharmaceuticals Strengt...
- D&D Pharmatech presented oral result...
- DuChemBio's ProstaSec, a radiopharm...
- [Greetings] Ildong Pharmaceutical
- Chaperone Launches Sports Recovery ...
- The Korea Pharmaceutical and Bio-Ph...
- A Yonsei University research team has...

Learn more

[Pharmaceutical Technology Licensing](#)

[Bio-company investment consulting](#)

[Buy vitamins and supplements](#)

[Clinical trial data analysis](#)

[therapy](#)

[Technology transfer contract consulting](#)

[Obesity Treatment Information](#)

[Obesity Management Program](#)

[obesity treatment](#)

[Research materials related to Messera](#)

EON 7 Builder Floors in Emaar Emerald Hills Sec 62 Gurugram

EON Developers | Sponsored

[Read the next document >](#)

Latest Recommended Sort by replies BEST comment

EON 7 Builder Floors in Emaar Emerald Hills Sec 62 Gurugram

EON Developers | Sponsored

Book Now

Flying to New Zealand? Read this first

Air New Zealand | Sponsored

Book Now

Conscientious Elaira located in Sec 80, Gurugram

Conscient Elaira | Sponsored

Secure Your Child's Future with Strong English Fluency

Planet Spark | Sponsored

Learn More

Delhi: This Intraday Strategy by Mr. Bala Could Boost Your Trading Success

TradeWise | Sponsored

Learn More

Conscientious Elaira: 3 BHK Homes@Sec 80, Gurgaon

Conscient Elaira | Sponsored

Media Introduction Report an article Advertising Inquiries Terms of Use privacy policy Youth Protection Policy Copyright Protection Policy Refusal of unauthori:



419, Building B, 167 Songpa-daero, Songpa-gu, Seoul (Munjeong Station Terra Tower) | Representative phone number: 02-2054-3583 | Fax: 02-2054-3584
Corporate name: The Bio Co., Ltd. | Title: THE BIO | Registration Number: Seoul A 54987 | Mail order number: 2023-Seoul Gangnam-04559 |
Business Registration Number: 626-87-02951
Registration Date: 2023-07-31 | Publication Date: 2023-09-04 | Publisher: Lee Young-seong | Editor: Lee Young-seong
Personal Information Protection Manager: Kang In-hyo | Youth Protection Officer: Kang In-hyo |

C o pyright © 2025 The Bio. All rights reserved. Email to lykyrose1@gmail.com



인터넷신문윤리위원회
윤리강령을 준수합니다

POWERED BY NC

EON 7 Builder Floors in Emaar Emerald Hills Sec 62 Gurugram

EON Developers | Sponsored

Read the next document >